Renal (pro)renin receptor contributes to development of diabetic kidney disease through transforming growth factor-β1 - connective tissue growth factor signalling cascade

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 4, 2011, Pages 215-221

  Huang, Jiqian ^a   Matavelli, Luis C ^a   Siragy, Helmy M ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

(pro)renin receptor; Connective tissue growth factor; Hyperglycaemia; Kidney; Mesangial cells; Transforming growth factor 1

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CONNECTIVE TISSUE GROWTH FACTOR; GLUCOSE; HANDLE REGION PEPTIDE; PRORENIN; PRORENIN RECEPTOR; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VALSARTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; HYPERGLYCEMIA; MALE; MESANGIUM CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; UPREGULATION;

ANIMALS; CONNECTIVE TISSUE GROWTH FACTOR; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; GLUCOSE; HYPERGLYCEMIA; MALE; MESANGIAL CELLS; OLIGOPEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, CELL SURFACE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TETRAZOLES; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION; VALINE;

EID: 79953035897     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05486.x     Document Type: Article

References (43)

1. Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 1998; 31: 181-8.
2. Wolf G. Link between angiotensin II and TGF-beta in the kidney. Miner. Electrolyte Metab. 1998; 24: 174-80.
3. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 2001; 38: 635-8.
4. Gaedeke J, Noble NA, Border WA. Angiotensin II and progressive renal insufficiency. Curr. Hypertens. Rep. 2002; 4: 403-7.
5. Wolf G, Mueller E, Stahl RA, Ziyadeh FN. Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J. Clin. Invest. 1993; 92: 1366-72.
6. Wolf G, Ziyadeh FN, Zahner G, Stahl RA. Angiotensin II-stimulated expression of transforming growth factor beta in renal proximal tubular cells: Attenuation after stable transfection with the c-mas oncogene. Kidney Int. 1995; 48: 1818-27.
7. Zhou Y, Poczatek MH, Berecek KH, Murphy-Ullrich JE. Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions. Biochem. Biophys. Res. Commun. 2006; 339: 633-41.
8. Naito T, Masaki T, Nikolic-Paterson DJ, Tanji C, Yorioka N, Kohno N. Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: A mechanism for activation of latent TGF-beta1. Am. J. Physiol. Renal Physiol. 2004; 286: F278-87.
9. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J. Clin. Invest. 1994; 93: 2431-7.
10. Ruiz-Ortega M, Lorenzo O, Egido J. Angiotensin III up-regulates genes involved in kidney damage in mesangial cells and renal interstitial fibroblasts. Kidney Int. Suppl. 1998; 68: S41-5.
11. Huang Y, Wongamorntham S, Kasting J et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 2006; 69: 105-13.
12. Ma J, Weisberg A, Griffin JP, Vaughan DE, Fogo AB, Brown NJ. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int. 2006; 69: 1064-72.
13. Chen S, Hong SW, Iglesias-de la Cruz MC, Isono M, Casaretto A, Ziyadeh FN. The key role of the transforming growth factor-beta system in the pathogenesis of diabetic nephropathy. Ren. Fail. 2001; 23: 471-81.
14. Gupta S, Clarkson MR, Duggan J, Brady HR. Connective tissue growth factor: Potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int. 2000; 58: 1389-99.
15. Murphy M, Godson C, Cannon S et al. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J. Biol. Chem. 1999; 274: 5830-4.
16. Wahab NA, Yevdokimova N, Weston BS et al. Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. Biochem. J. 2001; 359: 77-87.
17. Sharma K, Ziyadeh FN. Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. Am. J. Physiol. 1994; 267: F1094-01.
18. Border WA, Noble NA. Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. Kidney Int. 1998; 54: 1390-1.
19. Riser BL, Denichilo M, Cortes P et al. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J. Am. Soc. Nephrol. 2000; 11: 25-38.
20. Grotendorst GR, Okochi H, Hayashi N. A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ. 1996; 7: 469-80.
21. Grotendorst GR. Connective tissue growth factor: A mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev. 1997; 8: 171-9.
22. Yokoi H, Sugawara A, Mukoyama M et al. Role of connective tissue growth factor in profibrotic action of transforming growth factor-beta: A potential target for preventing renal fibrosis. Am. J. Kidney Dis. 2001; 38: S134-8.
23. Nguyen G, Delarue F, Berrou J, Rondeau E, Sraer JD. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int. 1996; 50: 1897-903.
24. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 2002; 109: 1417-27.
25. Siragy HM, Huang J. Renal (pro)renin receptor upregulation in diabetic rats through enhanced angiotensin AT1 receptor and NADPH oxidase activity. Exp. Physiol. 2008; 93: 709-14.
26. Huang J, Siragy HM. Glucose promotes the production of interleukine-1beta and cyclooxygenase-2 in mesangial cells via enhanced (Pro)renin receptor expression. Endocrinology 2009; 150: 5557-65.
27. Matavelli LC, Huang J, Siragy HM. (Pro)renin receptor contributes to diabetic nephropathy by enhancing renal inflammation. Clin. Exp. Pharmacol. Physiol. 2010; 37: 277-82.
28. Huang J, Siragy HM. Regulation of (pro)renin receptor expression by glucose-induced mitogen-activated protein kinase, nuclear factor-kappaB, and activator protein-1 signaling pathways. Endocrinology 2010; 151: 3317-25.
29. Ichihara A, Hayashi M, Kaneshiro Y et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J. Clin. Invest. 2004; 114: 1128-35.
30. Kaneshiro Y, Ichihara A, Sakoda M et al. Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats. J. Am. Soc. Nephrol. 2007; 18: 1789-95.
31. Yagi S, Morita T, Katayama S. Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress. Hypertens. Res. 2004; 27: 129-35.
32. Jin XH, McGrath HE, Gildea JJ, Siragy HM, Felder RA, Carey RM. Renal interstitial guanosine cyclic 3', 5'-monophosphate mediates pressure-natriuresis via protein kinase G. Hypertension 2004; 43: 1133-9.
33. Takahashi H, Ichihara A, Kaneshiro Y et al. Regression of nephropathy developed in diabetes by (Pro)renin receptor blockade. J. Am. Soc. Nephrol. 2007; 18: 2054-61.
34. Ichihara A, Kaneshiro Y, Takemitsu T et al. Contribution of nonproteolytically activated prorenin in glomeruli to hypertensive renal damage. J. Am. Soc. Nephrol. 2006; 17: 2495-503.
35. Ichihara A, Kaneshiro Y, Takemitsu T et al. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 2006; 47: 894-900.
36. Wilkinson-Berka JL, Heine R, Tan G et al. RILLKKMPSV influences the vasculature, neurons and glia, and (pro)renin receptor expression in the retina. Hypertension 2010; 55: 1454-60.
37. Feldt S, Maschke U, Dechend R, Luft FC, Muller DN. The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling. J. Am. Soc. Nephrol. 2008; 19: 743-8.
38. Muller DN, Klanke B, Feldt S et al. (Pro)renin receptor peptide inhibitor "handle-region" peptide does not affect hypertensive nephrosclerosis in Goldblatt rats. Hypertension 2008; 51: 676-81.
39. Advani A, Kelly DJ, Cox AJ et al. The (Pro)renin receptor: Site-specific and functional linkage to the vacuolar H+-ATPase in the kidney. Hypertension 2009; 54: 261-9.
40. Kinouchi K, Ichihara A, Sano M et al. The (pro)renin receptor/ATP6AP2 is essential for vacuolar H+-ATPase assembly in murine cardiomyocytes. Circ. Res. 2010; 107: 30-4.
41. Cruciat CM, Ohkawara B, Acebron SP et al. Requirement of prorenin receptor and vacuolar H+-ATPase-mediated acidification for Wnt signaling. Science 2010; 327: 459-63.
42. He W, Dai C, Li Y, Zeng G, Monga SP, Liu Y. Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J. Am. Soc. Nephrol. 2009; 20: 765-76.
43. Dai C, Stolz DB, Kiss LP, Monga SP, Holzman LB, Liu Y. Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. J. Am. Soc. Nephrol. 2009; 20: 1997-2008.